This approval builds upon the initial FDA approval of T-DXd in August 2022, which was granted for HER2-low breast cancer based on the DESTINY-Breast04 trial (NCT03734029) and included both HR-positive and HR-negative patients. Here, ERBB2 is linked to breast cancer.